Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | Unknown unknown |
Therapy | M2698 |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | not applicable |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | Advanced Solid Tumor | not applicable | M2698 | Phase I | Actionable | In a Phase I trial, M2698 (MSC2363318A) demonstrated safety and preliminary efficacy in a variety of advanced solid tumor patients (Ann. Oncol. 26 (Suppl 2): ii25-ii27, 2015). | detail... |
Unknown unknown | Advanced Solid Tumor | not applicable | M2698 | Phase I | Actionable | In a Phase I trial, M2698 (MSC2363318A) demonstrated safety and preliminary efficacy, with 19% (6/32) of advanced solid tumor patients remained on treatment for more than 180 days (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 370PD; NCT01971515). | detail... |
Unknown unknown | Advanced Solid Tumor | not applicable | M2698 | Preclinical | Actionable | In a preclinical study, MSC2363318A demonstrated sustained inhibition of S6K phosphorylation, and inhibited tumor growth in several human cancer xenograft models of breast, pancreatic, glioblastoma and ovarian cancers (Mol Cancer Ther 2013;12(11 Suppl):A162). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
Abstract A162: Identification of brain penetrant p70S6K/Akt inhibitor MSC2363318A. | Full reference... | |
A FIRST IN HUMAN, DOSE ESCALATION TRIAL OF MSC2363318A - A DUAL P70S6K/AKT INHIBITOR, FOR PATIENTS WITH ADVANCED MALIGNANCIES | Full reference... | |
Phase I dose escalation study of M2698, a p70S6K/AKT inhibitor, in patients with advanced cancer | Full reference... |